Abstract Details

Title Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington’s Disease

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 047

Objective

To evaluate real-world adherence patterns with the vesicular monoamine transporter 2 inhibitors tetrabenazine and deutetrabenazine among patients diagnosed with Huntington’s disease (HD).

Background Chorea, a hallmark of HD, involves sudden, involuntary movements that can affect any muscle, interfere with daily functioning, and increase the risk of injury. Tetrabenazine and deutetrabenazine are FDA-approved to treat chorea associated with HD. Compared to tetrabenazine, deutetrabenazine has a unique pharmacokinetic profile leading to more consistent systemic exposure, less frequent dosing, and a potentially more favorable safety/tolerability profile. Real-world adherence data for these medications are limited.

Design/Methods Insurance claims data from the Symphony Health Solutions Integrated Dataverse (05/2017-05/2019) were retrospectively analyzed for patients diagnosed with HD (ICD-10-CM code G10). Patients were categorized into cohorts based on treatment. Outcomes included proportion of days covered (PDC), adherence rate (PDC>80%), and discontinuation rates during the 6-month follow-up period (after 30-day dose stabilization period).

Results Patient demographic characteristics between the deutetrabenazine (n=281) and tetrabenazine (n=101) cohorts were comparable at baseline. Mean±SD PDC was significantly higher in the deutetrabenazine versus tetrabenazine cohort (78.5%±26.7% vs 69.3%±31.4%; P<0.01). Similarly, a higher adherence rate was observed in the deutetrabenazine versus tetrabenazine cohort, though the difference was not statistically significant (64.1% vs 55.4%; P=0.1518). Discontinuation rates were significantly lower in the deutetrabenazine versus tetrabenazine cohort during the 6-month follow-up period (1 month, 3.5% vs 9.2%; 3 months, 14.7% vs 23.3%; 6 months, 25.4% vs 37.2%; P<0.05).

Conclusions Results from this real-world analysis showed that patients with HD in the deutetrabenazine cohort were more adherent to treatment and had lower discontinuation rates compared with patients in the tetrabenazine cohort. However, a potential limitation is overestimated adherence, as claims for prescription fills may not capture actual use. Additional research is warranted to explore the differences in adherence patterns between treatments, which may inform treatment decision-making.

Authors/Disclosures
Sam Leo, PharmD (Teva) PRESENTER	Dr. Leo has received personal compensation for serving as an employee of Teva Pharmaceutical Industries.
Daniel O. Claassen, MD, F�鶹��ýӳ�� (Vanderbilt University Medical Center)	Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AskBio. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics . Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jessica K. Alexander, PhD (Jazz)	Jessica K. Alexander has received personal compensation for serving as an employee of Teva Pharmaceuticals. Jessica K. Alexander has received stock or an ownership interest from Teva Pharmaceuticals.

�鶹��ýӳ��

�鶹��ýӳ��